{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T16:22:00Z","timestamp":1756311720082,"version":"3.40.5"},"reference-count":20,"publisher":"S. Karger AG","issue":"10","license":[{"start":{"date-parts":[[2021,9,7]],"date-time":"2021-09-07T00:00:00Z","timestamp":1630972800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2021,9,7]],"date-time":"2021-09-07T00:00:00Z","timestamp":1630972800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Urol Int"],"published-print":{"date-parts":[[2022]]},"abstract":"<jats:p>&lt;b&gt;&lt;i&gt;Introduction:&lt;\/i&gt;&lt;\/b&gt; It was aimed to show the relationship between benign prostatic hyperplasia and inflammation by measuring urinary C-reactive protein values before and after alpha-blocker treatment. &lt;b&gt;&lt;i&gt;Methods:&lt;\/i&gt;&lt;\/b&gt; A total of 71 patients with a total prostate-specific antigen &amp;#x3c;3.5 ng\/mL, International Prostate Symptom Score &amp;#x3e;7, and maximum urinary flow rate &amp;#x3c;15 mL\/s were included in the study. Doxazosin 4 mg p.o. once daily was started orally as an alpha-blocker treatment. Serum and urine C-reactive protein values, International Prostate Symptom Score, maximum urinary flow rate, and the post-void residual volume of patients were recorded at the first admission and in the first month of alpha-blocker treatment. &lt;b&gt;&lt;i&gt;Results:&lt;\/i&gt;&lt;\/b&gt; The mean age of the patients was 59.2 \u00b1 7.5 years. The mean serum C-reactive protein values of the patients at the first admission and follow-up were 2.62 \u00b1 1.8 (range, 0\u20135) mg\/L and 2.83 \u00b1 1.6 (0\u20136) mg\/L, respectively. The mean urine C-reactive protein values of the patients at the first admission and follow-up were 0.45 \u00b1 0.11 (range, 0.28\u20130.99) mg\/L and 0.14 \u00b1 0.04 (range, 0.79\u20130.328) mg\/L, respectively, which was statistically significantly different. In the subgroup analysis, the urine C-reactive protein level change was more prominent in severely symptomatic patients than in moderately symptomatic patients. &lt;b&gt;&lt;i&gt;Conclusion:&lt;\/i&gt;&lt;\/b&gt; Our results showed that C-reactive protein was detectable in urine, alpha-blocker treatment significantly reduced urine C-reactive protein levels, and the decrease was more prominent in severely symptomatic patients. <\/jats:p>","DOI":"10.1159\/000518474","type":"journal-article","created":{"date-parts":[[2021,9,7]],"date-time":"2021-09-07T21:00:33Z","timestamp":1631048433000},"page":"992-996","source":"Crossref","is-referenced-by-count":2,"title":["What Is the Interaction between Urine C-Reactive Protein, Prostatic Inflammation, and Doxazosin Treatment in Patients with Benign Prostatic Hyperplasia? A Pilot Study"],"prefix":"10.1159","volume":"106","author":[{"given":"Ahmet","family":"Asfuroglu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1506-941X","authenticated-orcid":false,"given":"Melih","family":"Balci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yilmaz","family":"Aslan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cagdas","family":"Senel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ozer","family":"Guzel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammed Fevzi","family":"Kilinckaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Turan","family":"Turhan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Altug","family":"Tuncel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2021,9,7]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-063014-123902"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2008.03.057"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2007.06910.x"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2006.12.011"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0156918"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/S0969-2126(99)80023-9"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1097\/01.lab.0000081388.40145.65"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2015.03.103"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2007.11.026"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2014.06.026"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2006.07.016"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2009.02.064"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1159\/000167844"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/s1879-5226(10)60028-0"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1002\/pros.20110"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwp406"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwp085"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00754"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1172\/JCI18921"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1042\/CS20040315"}],"container-title":["Urologia Internationalis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/518474","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/518474","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T15:16:13Z","timestamp":1745421373000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000518474"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,7]]},"references-count":20,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2022,10,17]]},"published-print":{"date-parts":[[2022,10,19]]}},"URL":"https:\/\/doi.org\/10.1159\/000518474","archive":["Portico"],"relation":{},"ISSN":["0042-1138","1423-0399"],"issn-type":[{"type":"print","value":"0042-1138"},{"type":"electronic","value":"1423-0399"}],"subject":[],"published":{"date-parts":[[2021,9,7]]}}}